Scientific Evidence - The Clinic of Change

Scientific
Evidence

Partners

Transcranial Magnetic Stimulation in Lisbon | The Clinic of Change

When you search for "transcranial magnetic stimulation in Lisbon," the questions are always the same: what exactly is it, how does it work in the brain, who is it for, how much does it cost, and where can you find high-quality treatment?

TMS for Treatment-Resistant Depression | The Clinic of Change Lisbon

What lies behind depression that doesn’t respond to medication—and what should everyone know about TMS for depression available in Portugal?

TMS and Psychotherapy in Lisbon | The Clinic of Change

What the latest research reveals about the combination of TMS and psychotherapy—and why this approach may be more effective than either intervention on its own.

TMS for Anxiety and POC in Lisbon | The Clinic of Change

Transcranial Magnetic Stimulation goes far beyond depression. What scientific research reveals about TMS for anxiety, OCD, and addictive disorders—and what this means for Portuguese patients.

TMS: What to Expect from Treatment at The Clinic of Change

Everything you need to know before scheduling your first Transcranial Magnetic Stimulation appointment in Lisbon—from the initial evaluation to the end of the treatment cycle.

Psychedelics in the treatment of anorexia | Pioneering study on psilocybin

A study conducted by Shortwave Life Sciences is evaluating the effectiveness of psilocybin in treating anorexia. This naturally occurring psychedelic substance is derived from certain mushrooms.

Ketamine and treatment-resistant depression

The use of psychedelic drugs has been gaining traction in the treatment of mental illness. Ketamine is the most commonly used substance in psychotherapy, but studies seem to point to benefits in the clinical use of psilocybin for treating treatment-resistant depression, addictive behaviors, eating disorders, and pain management.

BPL-003: medicamento psicadélico para depressão resistente

In this new study, a 12-milligram dose of BPL-003 administered eight weeks after an initial dose of 12, 8, or 0.3 milligrams produced additional, rapid, and clinically relevant antidepressant effects that persisted for up to eight weeks.

Cetamina e escetamina melhoram qualidade de vida na depressão

A new study conducted by Canadian experts concludes that the use of ketamine and esketamine in the treatment of severe depression (major depressive disorder) and treatment-resistant depression can lead to a substantial improvement in patients’ quality of life.

ADHD: More than one million new diagnoses in recent years

In the United States, for example, it is estimated that about 1 in 9 children has already received this diagnosis. In Europe, too, the number of families seeking specialized evaluation has grown significantly. So, what explains this trend?

Cetamina e antidepressivos: novos mecanismos e tratamentos

The approval of esketamine (Spravato) and brexanolone (Zulresso) in 2019 paved the way for substances such as psilocybin and MDMA, which could be the next to receive regulatory approval.

Cetamina aprovada em Portugal para depressão resistente

The discovery of ketamine’s antidepressant potential has not only expanded treatment options but has also challenged and revitalized the theoretical foundations of psychiatry.

Escetamina: uma alternativa eficaz no tratamento da depressão

A case study published in the journal *Frontiers in Psychiatry* has underscored the therapeutic potential of intranasal esketamine as a viable alternative in cases of high treatment resistance.

Research on psychedelic-assisted psychotherapy highlights the importance of describing therapeutic techniques

The use of psychedelic drugs has been gaining traction in the treatment of mental illness. Ketamine is the most commonly used substance in psychotherapy, but studies seem to point to benefits in the clinical use of psilocybin for treating treatment-resistant depression, addictive behaviors, eating disorders, and pain management.

SCIENTIFIC EVIDENCE

Explore the most relevant international scientific articles on ketamine-assisted psychotherapy.

Ketamine-Assisted Psychotherapy Delivers Lasting Results in the Treatment of Anxiety, Depression, and Post-Traumatic Stress

Ketamine-assisted psychotherapy provides lasting benefits in the treatment of anxiety, depression, and post-traumatic stress disorder for up to three to six months after treatment.

KETAMINE FOR DEPRESSION: Facts, Questions, Possibilities, Barriers, and Opportunities

This scientific article, published in JAMA Psychiatry, underscores the importance of the potential offered by ketamine-assisted psychotherapy in the treatment of depression.

PSYCHEDELIC-ASSISTED PSYCHOTHERAPY AND NEUROSCIENCE

A collection of studies on the relationship between these two sciences.

THE EFFECT OF KETAMINE ON SLEEP IN THE TREATMENT OF RESISTANT DEPRESSION

A systematic review of how ketamine may reduce the severity of insomnia in patients with depression.

KETAMINE IN THE TREATMENT OF PSYCHIATRIC DISORDERS AND ADDICTIONS

Presentation of the study published by Cambridge University Press.